| 2006-12-12: |
New Study Shows Clexane( R ) / Lovenox( R ) ( Enoxaparin Sodium Injection ) is More Effective Than Unfractionated Heparin ( UFH ) for Preventing the Risk of Venous Thromboembolism ( VTE ) in Patients With Acute Ischemic Stroke
Orlando, Florida ( PRN/ots ) - - The PREVAIL Study Showed That in Acute Ischemic Stroke Patients Treated With Clexane( R ) / Lovenox( R ), the Risk of Having a VTE was Lowered by a Significant 43 Prozent With no Significant Increase in Clinically Important Bleedings When Compared to UFH (...) |
| 2007-06-02: |
Avastin( R ) Significantly Prolongs Progression Free Survival in Advanced Kidney Cancer
Chicago ( PRN/ots ) - - Patients Have a Chance to Live Almost Twice as Long Without Their Disease Returning Adding Avastin ( bevacizumab ) to interferon offers patients with advanced renal cell cancer the chance to live twice as long without their disease advancing ( "progression free (...) |
| 2010-09-12: |
Vandetanib Phase II Trial Shows Significant Improvement of Progression Free Survival in Patients With Advanced Papillary or Follicular Thyroid Cancer
Paris ( PRN/ots ) - AstraZeneca today announced results from a phase II study evaluating the investigational drug vandetanib for the treatment of patients with locally advanced or metastatic papillary or follicular thyroid cancer. This study, ZACTHYF, showed that treatment with vandetanib significantly improved Progression Free Survival (...) |
| 2004-09-16: |
Degussa enters into research alliance with Korean partner / Targeting the next generation of materials for electronics applications
Dusseldorf ( na Originaltextservice ) - Degussa AG, Dusseldorf, Germany and LG Chem, Ltd., Seoul, Korea, have agreed on joint strategic research into the next generation of highly functional materials for electronics and IT applications. The aim is to develop products and systems solutions for and with the (...) |
| 2005-10-24: |
New Melatonergic Antidepressant Combines Efficacy With Very Favourable Side - Effect Profile
Amsterdam, The Netherlands ( PRN/ots ) - - Valdoxan( R ) ( agomelatine ) Provides Antidepressant Efficacy With the Additional Clinical Benefit of Sleep Improvement With no Effect on Daytime Vigilance The first melatonergic antidepressant, Valdoxan( R ) ( agomelatine ), offers an innovative new approach to the treatment of depression. Valdoxan combines antidepressant (...) |
| 2006-11-21: |
Isotechnika Receives Notice of Allowance for mTOR Inhibitor, TAFA93
Edmonton, Alberta, November 21 ( PRN/ots ) - Isotechnika Inc. ( TSX: ISA ) today announced the Company has received a Notice of Allowance from the United States Patent and Trademark Office based on U.S. Patent Application Serial No. 10/845,747 for TAFA93, including both composition of matter (...) |
| 2010-11-15: |
Burcon and ADM Enter Into CLARISOY( R ) Letter of Intent
Vancouver, November 15 ( PRN/ots ) - Burcon NutraScience Corporation ( "Burcon" ) announced today that it has signed a non - binding letter of intent ( the "Letter of Intent" ) with Archer Daniels Midland Company ( "ADM" ) which details the intention of the two parties to enter into a license (...) |
| 2006-11-15: |
TMC125 Can Be Used in Combination with Most Antiretrovirals
Glasgow, Scotland, November 15 ( PRN/ots ) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug - drug interaction studies involving the investigational non - nucleoside reverse transcriptase inhibitor ( NNRTI ) TMC125 was presented today as a plenary oral (...) |
| 2008-08-19: |
New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain
Indianapolis ( PRN/ots ) - - Study with duloxetine evaluating long - term pain reduction in treatment of DPNP is first to exceed three months Duloxetine hydrochloride maintained pain reduction in the treatment of diabetic peripheral neuropathic pain ( DPNP ) for more than six months,( 1 ) according to (...) |
| 2007-04-16: |
Lilly and the AACR Work Together To Recognize Breakthrough Research in the Fight Against Cancer
Los Angeles ( PRN/ots ) - - Awards Presented for Substantial Contributions to Cancer Research Innovative and collaborative cancer research can be the catalyst to improving patient outcomes. Celebrating the 100th anniversary of the American Association for Cancer Research ( AACR ) at the 2007 AACR Annual Meeting (...) |
| 2006-09-05: |
Roche Requests Re - Examination of CHMP Opinion on Tarceva in Pancreatic Cancer at the European Medicines Agency
Basel, Switzerland ( PRN/ots ) - - First Treatment for Years to Have Shown a Significant Survival Benefit for Patients Roche announced today that it has requested a re - examination of the data supporting the filing of their breakthrough cancer medicine, Tarceva, for the treatment (...) |
| 2006-08-09: |
Archbishop Desmond Tutu Launches 100,000 Cataract Operations in 100 days
Cape Town, South Africa ( PRN/ots ) - "We can really do something to change the world," says Archbishop Desmond Tutu. "I think not being able to see is one of the most debilitating disabilities in our world today," Archbishop Tutu said at the launching of (...) |
| 2005-01-26: |
Isotechnika Completes Recruitment for Phase III Psoriasis Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that the Company has completed recruitment for its Canadian Phase III psoriasis trial for its lead immunosuppressive compound, ISA247. Of the 400 subjects enrolled in the trial, 207 subjects have commenced treatment. The Company received a (...) |
| 2008-09-10: |
Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS( R ) and APIDRA( R ) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
Paris ( PRN/ots ) - - Abstracts 185 and 1112 Sanofi - aventis, a world leader in diabetes care, announced results from two randomized clinical studies presented at the European Association for the Study of Diabetes ( EASD ) 44th Annual Meeting demonstrating that the "basal plus" insulin (...) |
| 2006-10-17: |
Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
New York ( PRN/ots ) - Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy. Ranbaxy can appeal (...) |
| 2008-09-26: |
Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
London ( PRN/ots ) - - World Contraception Day 2008 Highlights Scale and Impact of Unplanned Pregnancy Today, international sexual and reproductive health experts and successful recording artist and media personality Kelly Osbourne, call for more action to address the burgeoning problem of unplanned pregnancies and (...) |
| 2006-10-13: |
Bristol - Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for its Ultrasound Contrast Agent Luminity( TM )( Perflutren Lipid Microsphere )
N. Billerica, Massachusetts ( PRN/ots ) - Bristol - Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY( TM ), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established coronary artery disease. "With LUMINITY, (...) |
| 2010-08-17: |
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Indianapolis, August 17, 2010 ( PRN/ots ) - Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long - term Phase III studies showed it did not slow (...) |
| 2006-12-20: |
sanofi pasteur Influenza Vaccine Production Tops 170 Million Doses in 2006
Lyon, France and Swiftwater, Pennsylvania ( PRN/ots ) - - Record Production Capabilities Strengthen sanofi pasteur's Global Leadership in the Fight Against Seasonal Influenza and Place the Company at the Forefront of Pandemic Readiness sanofi pasteur, the vaccines business of the sanofi - aventis Group ( NYSE: (...) |
| 2008-11-12: |
Tibotec Data Presented at ICAAC and HIV9 Follow key Regulatory Approvals for Anti - HIV Compounds
Glasgow, Scotland, November 12 ( PRN/ots ) - - Not Intended for Journalists in the UK or Ireland - New Findings From ARTEMIS and TITAN Studies Demonstrate Growth of the Tibotec Virology Franchise New data on PREZISTA( R ) ( darunavir ), a protease inhibitor from Tibotec, will be (...) |
| 2005-07-05: |
Thoracic Cancer Patients Find New Reasons for Hope with Alimta( R )
Barcelona ( PRN/ots ) - - New data may provide important treatment advances in mesothelioma and lung cancer Patients with a cancer of the lining of the lung, known as malignant pleural mesothelioma ( MPM ), lived longer than previously reported( 1 ), when treated with Eli Lilly and (...) |
| 2009-02-13: |
Study Proves Longer Prophylactic Therapy With Valcyte Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
Basel, Switzerland ( PRN/ots ) - - Doubling Duration of Valcyte Therapy Provides Significant Benefit to Patients Compared to Current Standard of Care - For Non - US Media Only Roche announced today that a Phase III study investigating the efficacy and safety of extended preventative (...) |
| 2008-10-28: |
Therapure Biopharma Inc. Announces Collaboration With Induce Biologics Inc.
Toronto, Canada ( PRN/ots ) - - Ontario Biotech Companies Work Together on Innovative Bone Protein Technology TORONTO, Canada, October 28 /PRNewswire/ - - Thomas Wellner, President and CEO of Therapure BioPharma Inc. and Dr. Cameron Clokie, President and CEO of Induce Biologics Inc. today announced a (...) |
| 2008-04-26: |
New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment Response That Comes as Close to a Cure as Possible
Basel, Switzerland ( PRN/ots ) - - No Nucleoside/Nucleotide Analogue Treatments Have Shown Similar Results New data revealed today show that a significant number of patients with chronic hepatitis B virus infection who received PEGASYS( R ) ( peginterferon alfa - 2a ) treatment achieved clearance of a blood antigen (...) |
| 2008-07-09: |
Industry Leaders Select Resverlogix's RVX - 208 Among Top 10 Most Promising Drugs
Calgary, Canada ( PRN/ots ) - Resverlogix Corp's ( "Resverlogix" or the "Company" ) ( TSX:RVX ) novel lead ApoA - I drug candidate, RVX - 208 has been selected as one of the top 10 most promising cardiovascular disease ( CVD ) drugs available for strategic partnering by an independent committee assembled (...) |
| 2010-04-29: |
European Workers Would Trade Money for an Early Retirement
Rotterdam, The Netherlands, April 29, 2010 ( PRN/ots ) - The lure of retirement is simply too much for many Europeans with almost one in three workers ( 29 Prozent ) saying they would prefer their government not to raise the national retirement age, and would be happy (...) |
| 2005-11-17: |
Experts Call for Re - Focussing of COPD Management to Reduce Hospital Admissions and Mortality
Lund, Switzerland, November 17 ( PRN/ots ) - For Non - US Medical Journalists Only A new report on the importance of treating Chronic Obstructive Pulmonary Disease ( COPD ) exacerbations is launched today, on World COPD Day. Global dissemination of the report to family physicians/General Practitioners around (...) |
| 2008-12-03: |
Wyeth Submits European Marketing Authorization Application for its 13 - Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
Collegeville, Pennsylvania ( PRN/ots ) - - Approval sought for investigational vaccine for protection against the 13 most prevalent serotypes associated with serious pneumococcal disease Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it has submitted a marketing authorization application ( MAA ) to the (...) |
| 2009-03-20: |
Experts Unite to Create New Online Resource for Restless Legs Syndrome
Ingelheim, Germany ( PRN/ots ) - - Unique Educational Website 'Under the Covers of Restless Legs Syndrome ( RLS )' is Launched on World Sleep Day - For Non - US Healthcare Media The website http://www.rlsunderthecovers.com brings together leading medical experts in the field of Restless Legs (...) |
| 2004-09-03: |
New European Study Examines the Role of Insulin Resistance in Predicting Cardiovascular Disease
London and Brussels ( PRN/ots ) - - RISC Study, Largest of its Kind, Reaches Recruitment Milestone The European Group for the study of Insulin Resistance ( EGIR ) announced today that the clinical trial recruitment milestone of 1,200 subjects has been reached in the Relationship (...) |
| 2007-04-13: |
SEBIVO( R ) Demonstrated Better Antiviral Activity Compared to Adefovir in Patients With Chronic Hepatitis B; New Data Presented
Barcelona, Spain ( PRN/ots ) - - SEBIVO Suppressed Virus More Rapidly and Profoundly Than Adefovir( 1 ) - Rapid and Powerful Viral Suppression Led to Better Treatment Outcomes( 2 ) - SEBIVO Has Been Recommended for Approval by European Medicines Agency, Pending Final Approval by the European Commission In a (...) |
| 2007-02-26: |
Fourth Phase III Study of Vandetanib ( ZACTIMA( TM ), ZD6474 ) in Patients With Advanced Lung Cancer
Alderley Park, England ( PRN/ots ) - - A Phase III international, parallel group, randomised, double - blind study of vandetanib in combination with pemetrexed for advanced non - small cell lung cancer ( NSCLC ) after failure of first line anti - cancer therapy AstraZeneca today announced that a (...) |
| 2006-08-10: |
Dutch Biopharmaceutical Company AM - Pharma Strengthens Intellectual Property Position for Lactoferrin Derived Antimicrobial Peptide hLF1 - 11
Bunnik, The Netherlands ( PRN/ots ) - AM - Pharma B.V., a biopharmaceutical company engaged in the pre - clinical and early clinical development of novel compounds to treat infectious and inflammatory diseases, announces the issuance of the patent for one of its lead products, the antimicrobial peptide (...) |
| 2007-06-15: |
Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Malvern, Pennsylvania ( PRN/ots ) - Solstice Neurosciences, Inc. today reported important results from a multicenter, forced dose escalation study of Botulinum Toxin Type B Injectable Solution ( Myobloc( R ) ) recently presented at the 11th International Congress of The Movement Disorders Society in Istanbul, Turkey. This was (...) |
| 2010-07-15: |
Takeda Responds to FDA Advisory Committee Recommendation
London, July 15, 2010 ( PRN/ots ) - The U.S. Food and Drug Administration ( FDA ) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular ( CV ) safety of rosiglitazone, as presented (...) |
| 2009-09-22: |
Denosumab Demonstrates Superiority Over Zometa( R ) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Thousand Oaks, California ( PRN/ots ) - Amgen ( Nasdaq: AMGN ) today announced detailed results from a Phase 3, head - to - head trial evaluating denosumab versus Zometa( R ) ( zoledronic acid ) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its (...) |
| 2004-09-06: |
Doctors Discuss Controversial and Radical Solutions in a Bid to Alleviate the Kidney Organ Shortage
Vienna, Austria ( PRN/ots ) - Transplant specialists from around the world met yesterday to discuss controversial, radical and novel approaches to minimise the impact of the current organ shortage problem in a bid to help desperate patients in need of a kidney transplant. The full - (...)
- Who gets a transplant, who doesn't and who shouldn't? - How do we define candidacy in an era of limited resources? - Can we more effectively manage transplant waiting lists and the patients on them? - How do we deal with donor - recipient incompatibility and antibody - mediated rejection? - Should we embrace non - heart - beating donation? - How far can donor criteria be extended? - Should recipient risk factors influence the quality of the organ offered?
In his closing remarks, co - chair Associate Professor Jonas Wadström explained, "The shortage of kidneys has led the transplant community to explore new and innovative practices and techniques to expand the organ donor pool. Optimising donor allocation and utilising extended - criteria donors and non - heart - beating donors are just some of the avenues being explored to try and navigate a way forward to help patients with end - stage renal disease". The 'Controversies in Renal Transplantation' initiative will run for 3 years and will comprise a series of educational meetings to be held internationally. The goal of the programme aims to generate discussion, education and awareness of the controversial aspects of kidney transplantation amongst the medical community and among patients and potential donors. This important initiative is the latest step in Fujisawa's pioneering activities to help expand the kidney - donor pool. Notes to Editors: The 'Controversies in Renal Transplantation' initiative follows a highly successful series of meetings on innovations in living - donor kidney transplantation, also supported by Fujisawa. The steering committee members are: Professor R.S. Gaston ( Alabama, USA ); Associate Professor J. Wadström ( Uppsala, Sweden ); Professor U.A. Frei ( Berlin, Germany ); Professor A.J. Matas ( Minneapolis, USA ); Professor M.L. Nicholson ( Leicester, UK ); and Dr A. Sugitani ( Fukuoka, Japan ). More information is available at www.livekidney.com or media@fujisawa.de Fujisawa GmbH is a subsidiary of Fujisawa Pharmaceutical Co., Ltd., based in Osaka, Japan. Fujisawa Pharmaceutical Co., Ltd. is among the world's top 30 pharmaceutical companies and employs over 8000 people in Japan, Europe, North America and Asia. Since its launch of Prograf( r ) in Japan in 1993, the first in the world, Fujisawa has become one of the world's leading transplant and immunosuppression companies. Fujisawa plans to maintain its commitment to transplantation, and is dedicated both to improving the results of solid - organ transplantation and to ensuring the health and quality of life of patients. Prograf( r ) is currently available in nearly 70 countries and forms the centerpiece of Fujisawa's continuing growth. Additional information on Fujisawa GmbH can be found on the Company's Web site at www.fujisawaeurope.com. www.fujisawaeurope.com ots Originaltext: Fujisawa GmbH Im Internet recherchierbar: http://www.presseportal.de Contact: Marite Ode, Fujisawa GmbH, PR+Communications, T: +49 - 89 - 45442249, F: +49 - 89 - 45442030, media@fujisawa.de |
| 2007-10-10: |
New Survey Conveys Fundamental Shift in the Perceptions of Treatment Outcomes in Schizophrenia
Leuven, Belgium ( PRN/ots ) - - EUFAMI Survey Shows Carers Across Europe Believe in Remission as a Realistic Treatment Goal for Many People Living With Schizophrenia A large majority of families who care for someone with schizophrenia are confident that many people with (...) |
| 2005-10-07: |
The Lancet Publishes Groundbreaking Proactive Study Showing Type - 2 Diabetes Treatment Significantly Reduces Risk of Non - Fatal Heart Attacks, Strokes and Deaths
London ( PRN/ots ) - - Takeda's ACTOS( R ) ( pioglitazone HCl ) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS( R ) ( pioglitazone HCl ), an oral glucose lowering medication, significantly reduces the combined risk of non - fatal (...) |
| 2005-09-26: |
FDA Accepts for Filing a License Application for New Pediatric Combination Vaccine, PENTACEL( TM )
Lyon, France et Swiftwater, Pennsylvanie ( PRN/ots ) - - First Combination Vaccine Candidate in the U.S. Designed to Protect Infants and Young Children against Diphtheria, Tetanus, Pertussis, Polio, and Hib Sanofi pasteur, the vaccines business of the sanofi - aventis Group ( EURONEXT: SAN ), ( NYSE: SNY ), (...) |
| 2007-09-28: |
Eisai Announce Establishment of New Pharmaceutical Marketing Subsidiary in Belgium
London ( PRN/ots ) - - For the Attention of Business and Healthcare Editors Eisai Co., Ltd. ( Headquarters: Tokyo, President & CEO: Haruo Naito ) announced today that the Company established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium. Eisai SA/NV is owned by (...) |
| 2006-11-28: |
Study Shows Pregabalin Effective in Difficult - to - Treat Nerve Pain
Sydney, Australia, November 28 ( PRN/ots ) - - Results Offer Hope to Patients With Excruciating Chronic Pain Findings from a new study published today in the journal Neurology demonstrate that the oral medication pregabalin is significantly effective in relieving central neuropathic ( nerve ) pain (...) |
| 2006-07-12: |
New Indication for Breast Cancer Drug, Arimidex( TM ), Offers New Treatment Choice for Tamoxifen Patients in EuropeNew Indication for Breast Cancer Drug, Arimidex( TM ), Offers New Treatment Choice for Tamoxifen Patients in Europe
Macclesfield, England ( PRN/ots ) - - Thousands More Women Will Have the Opportunity to Take 'Arimidex' as Part of Their Breast Cancer Treatment and Improve Their Chances of Living Longer, Cancer Free - For Health Professional and Consumer Press - For International Journalists - Not for (...) |
| 2006-09-28: |
PHASE III Study Compares Vandetanib ( Zactima( TM ), ZD6474 ) to Erlotinib in Advanced Lung Cancer
Alderley Park, England ( PRN/ots ) - - First Patient Enrolled in Pivotal International Randomised, Double - Blind Study of Vandetanib Versus Erlotinib FOR NON - US HEALTHCARE PROFESSIONAL PRESS ONLY AstraZeneca ( NYSE:AZN ) today announced the start of enrolment into a new Phase III study (...) |
| 2006-08-17: |
Osteoporosis Treatment Now Approved in Europe & US for Men
Paris, France ( PRN/ots ) - - Male Osteoporosis: Neglected and Under Treated PARIS, France, August 17 /PRNewswire/ - - The US Food and Drug Administration ( FDA ) this week approved Actonel( R ) 35mg ( risedronate sodium tablets ) for 'treatment to increase bone mass in men with osteoporosis'. This (...) |
| 2010-06-30: |
Mars hosts key scientific panel discussion at one of the largest ever gatherings of Nobel Laureates
Lindau, Germany ( na Originaltextservice ) - - Bildmaterial ist abrufbar unter http://www.presseportal.de/galerie.htx?type=obs - To tackle the world's most pressing issues, genuine collaboration between the academic community, government and industry is needed, Mars, Incorporated said yesterday. As part of (...) |
| 2010-10-07: |
International Menopause Society Calls Upon Medical Community to Improve the Vaginal Health of Postmenopausal Women
London ( PRN/ots ) - To mark World Menopause Day on 18th October 2010, the International Menopause Society ( IMS ) is launching new Recommendations for the management of postmenopausal vaginal atrophy, a distressing condition that will affect up to half of women after menopause.[1] This new (...) |
| 2008-11-10: |
Unique New Initiative by World - Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today
New Orleans and Los Angeles, November 10 ( PRN/ots ) - - Current Treatment Fails to Abolish Majority of Vascular Risk - Residual Risk Reduction Initiative ( R3i ) Calls for Action to Reduce the Lipid - Related Residual Vascular Risk Unaddressed by Current Standards of Care in (...) |
| 2008-08-05: |
TMC278 Demonstrates Long - Term Efficacy and Tolerability in Treatment - Naïve Adults With HIV
Mexico City, Mexico ( PRN/ots ) - - Ninety - Six - Week Data on Tibotec Investigational NNRTI Presented at AIDS 2008 New phase IIb data from Tibotec Pharmaceuticals Ltd. show that TMC278, the company's once - daily, investigational non - nucleoside reverse transcriptase inhibitor ( NNRTI ), provides long - term (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
